Gerresheimer Shares Surge on Acquisition Speculation Amid Deepening Accounting Crisis

Gerresheimer shares swing as a 41€/share Silgan bid rumor clashes with a major BaFin accounting investigation and 240M euro impairments, putting the firm at a crossroads.

Shares in Gerresheimer AG experienced significant volatility this week, caught between burgeoning takeover rumors and a severe accounting scandal that has drawn intensified regulatory scrutiny. The German packaging specialist finds itself at a critical juncture, with its financial reporting under a microscope and a potential suitor reportedly waiting in the wings.

A Premium Offer on the Horizon?

Market attention was captured by reports from Reuters, citing insider sources, that U.S. packaging giant Silgan Holdings is considering a bid for Gerresheimer. The potential offer is said to be around 41 euros per share. This figure represents a substantial premium, more than double the recent trading price, which had fallen below 19 euros. That decline was precipitated by the company's removal from Germany's SDAX index, which triggered forced selling by index-tracking funds. Whether these discussions will materialize into a formal bid remains highly uncertain, given the opaque state of Gerresheimer's financial accounts.

Regulatory Storm Intensifies

The speculation arrives as Gerresheimer's regulatory troubles deepen. Germany's Federal Financial Supervisory Authority (BaFin) has significantly expanded its audit of the company's interim financial statements. The probe, initially focused on contentious "bill-and-hold" contracts, now also encompasses the accounting of lease liabilities, capitalized development costs, and omitted depreciation charges. For the 2024 financial year alone, the investigation involves revenue misstatements totaling 35 million euros.

In a related development, the Auditor Oversight Body (APAS) has initiated proceedings against Gerresheimer's auditor, KPMG. The action stems from KPMG's issuance of an unqualified audit opinion on the now-questioned financial statements. To help untangle the complex situation, the company has engaged the audit firm Grant Thornton.

Financial Fallout and Shareholder Action

The necessary accounting corrections are having a profound impact on the balance sheet. Gerresheimer anticipates non-cash impairment charges between 220 and 240 million euros. These massive writedowns are primarily linked to technology projects at its Swiss subsidiary, Sensile Medical, and the planned closure of a U.S. glass plant scheduled for late 2026. In response to this crisis, the German shareholder association DSW is already examining potential damage claims against former executives, including ex-CEO Dietmar Siemssen.

Critical Deadlines Loom

While the company's revenue forecast of 2.3 to 2.4 billion euros for 2026 remains officially confirmed, it is explicitly conditional on successful bank negotiations and the absence of further BaFin-mandated corrections. A crucial milestone is set for June 2026, by which time management must present a fully audited annual report and the results of ongoing credit discussions. The firm's immediate financial flexibility will become starkly clear with the publication of its half-year report, currently scheduled for July 14th.